Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Oprozomib (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Amgen

10 Feb 2021 Status changed to discontinued as program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimizationand thus enrollment in OPZ003 was halted during dose-escalation.
25 Sep 2019 Status changed from active, no longer recruiting to completed.
08 Aug 2019 Planned End Date changed from 31 Jul 2019 to 23 Sep 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com